Enhabit, Inc.

DB:X34 Stock Report

Market Cap: €371.3m

Enhabit Valuation

Is X34 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of X34 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: X34 (€7.3) is trading below our estimate of fair value (€18.33)

Significantly Below Fair Value: X34 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for X34?

Key metric: As X34 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for X34. This is calculated by dividing X34's market cap by their current revenue.
What is X34's PS Ratio?
PS Ratio0.4x
SalesUS$1.04b
Market CapUS$386.18m

Price to Sales Ratio vs Peers

How does X34's PS Ratio compare to its peers?

The above table shows the PS ratio for X34 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average0.9x
SYAB SYNLAB
0.9x4.4%€2.5b
V3V VITA 34
0.9x3.1%€71.8m
FME Fresenius Medical Care
0.7x3.9%€13.0b
M12 M1 Kliniken
0.9x8.0%€308.0m
X34 Enhabit
0.4x4.2%€386.2m

Price-To-Sales vs Peers: X34 is good value based on its Price-To-Sales Ratio (0.4x) compared to the peer average (0.9x).

Price to Sales Ratio vs Industry

How does X34's PS Ratio compare vs other companies in the DE Healthcare Industry?

2 CompaniesPrice / SalesEstimated GrowthMarket Cap
EIF MedNation
0.1xn/aUS$4.72m
TLIK Arzneiwerk VIDA
0.07xn/aUS$4.06m
No more companies available in this PS range
X34 0.4xIndustry Avg. 0.6xNo. of Companies3PS00.40.81.21.62+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: X34 is good value based on its Price-To-Sales Ratio (0.4x) compared to the European Healthcare industry average (0.6x).

Price to Sales Ratio vs Fair Ratio

What is X34's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

X34 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.4x
Fair PS Ratio1x

Price-To-Sales vs Fair Ratio: X34 is good value based on its Price-To-Sales Ratio (0.4x) compared to the estimated Fair Price-To-Sales Ratio (1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst X34 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€7.30
€8.44
+15.6%
9.0%€9.48€7.58n/a5
Dec ’25€6.90
€8.16
+18.3%
8.9%€9.44€7.55n/a5
Nov ’25€6.10
€8.24
+35.2%
11.4%€10.02€7.29n/a5
Oct ’25€7.00
€8.34
+19.2%
10.9%€9.96€7.25n/a6
Sep ’25€7.45
€8.33
+11.8%
10.9%€9.95€7.24n/a6
Aug ’25€9.20
€8.58
-6.8%
14.3%€11.21€7.48n/a7
Jul ’25€8.05
€8.58
+6.5%
14.3%€11.21€7.48n/a7
Jun ’25€8.20
€8.65
+5.5%
13.2%€11.14€7.43n/a7
May ’25€9.50
€10.00
+5.3%
16.3%€12.82€7.78n/a7
Apr ’25€10.50
€10.00
-4.7%
16.3%€12.82€7.78n/a7
Mar ’25€8.15
€9.89
+21.4%
20.4%€13.76€7.34n/a7
Feb ’25€9.15
€9.89
+8.1%
20.4%€13.76€7.34n/a7
Jan ’25€9.40
€9.89
+5.3%
20.4%€13.76€7.34n/a7
Dec ’24€9.60
€9.45
-1.5%
23.2%€13.83€7.38€6.906
Nov ’24€6.85
€10.34
+51.0%
24.6%€14.21€6.63€6.106
Oct ’24€10.90
€10.53
-3.4%
24.3%€14.97€7.49€7.006
Sep ’24€11.60
€10.43
-10.1%
22.4%€14.70€7.35€7.457
Aug ’24€12.30
€12.05
-2.1%
22.1%€15.38€8.60€9.208
Jul ’24€10.80
€12.77
+18.3%
25.4%€18.33€8.71€8.058
Jun ’24€9.85
€13.62
+38.3%
21.1%€18.43€8.75€8.207
May ’24€11.00
€14.11
+28.3%
19.7%€18.13€9.97€9.507
Apr ’24€11.90
€15.07
+26.7%
17.4%€18.84€11.31€10.508
Mar ’24€14.20
€15.10
+6.3%
18.3%€18.70€11.22€8.157
Feb ’24€13.90
€14.77
+6.3%
16.3%€18.63€11.18€9.157
Jan ’24€12.10
€14.51
+19.9%
17.0%€18.72€11.23€9.406
Dec ’23n/a
€16.66
0%
15.9%€20.51€13.33€9.604

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/30 00:04
End of Day Share Price 2024/12/30 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Enhabit, Inc. is covered by 12 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joanna Sylvia GajukBofA Global Research
Jason CassorlaCitigroup Inc
Lawrence SolowCJS Securities, Inc.